Microbot Medical Inc. Files S-1/A Amendment

TL;DR

<b>Microbot Medical Inc. has filed an S-1/A amendment on April 1, 2024, providing updated information for regulatory purposes.</b>

AI Summary

Microbot Medical Inc. (MBOT) filed a Amended IPO Registration (S-1/A) with the SEC on April 1, 2024. Microbot Medical Inc. filed an S-1/A amendment on April 1, 2024. The company is incorporated in Delaware (DE). Its fiscal year ends on December 31st. The filing is related to the Securities Act of 1933. The company's business address is in Hingham, MA.

Why It Matters

For investors and stakeholders tracking Microbot Medical Inc., this filing contains several important signals. This filing indicates ongoing regulatory compliance and potential future corporate actions. The S-1/A form suggests the company may be preparing for a securities offering or significant corporate event.

Risk Assessment

Risk Level: low — Microbot Medical Inc. shows low risk based on this filing. The filing is an amendment (S-1/A) which typically updates previously filed information rather than introducing entirely new material risks.

Analyst Insight

Monitor for further amendments or filings that may reveal specific details about the company's strategic direction or financial activities.

Key Numbers

• 2024-04-01 — Filing Date (Date of S-1/A filing)
• 1231 — Fiscal Year End (Company's fiscal year end)
• 0000883975 — Central Index Key (Company's Central Index Key)
• 333-277190 — SEC File Number (SEC File Number for the registration)

Key Players & Entities

• Microbot Medical Inc. (company) — Filer name
• 0000883975 (company) — Central Index Key
• 3841 (regulator) — Standard Industrial Classification
• DE (regulator) — State of Incorporation
• S-1/A (regulator) — Form Type
• 333-277190 (regulator) — SEC File Number
• 24806806 (regulator) — Film Number
• 908-938-5561 (dollar_amount) — Business Phone

FAQ

Industry Context

Microbot Medical Inc. operates in the surgical and medical instruments and apparatus industry.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities.

What Investors Should Do

1. Review the full S-1/A filing for specific details on any updates or changes.
2. Monitor future SEC filings from Microbot Medical Inc. for further developments.
3. Research the company's industry and competitive landscape.

Key Dates

• 2024-04-01: S-1/A Filing — Amendment to previous registration statement filed by Microbot Medical Inc.

Year-Over-Year Comparison

This is an amendment (S-1/A) to a previous filing, indicating updates rather than a new initial filing.

Key Financial Figures

• $0.01 — o 1,005,965 shares of our common stock, $0.01 par value per share, representing share
• $1.15 — stock on the Nasdaq Capital Market was $1.15. Investing in our common stock involv
• $6.75 million — f the SPA and return of the Plaintiffs' $6.75 million purchase price with respect to the Fina
• $2,154,000 — Company paid Plaintiffs an aggregate of $2,154,000 (the "Total Settlement Amount"), consis
• $1,100,000 — d by the Company's insurance carrier of $1,100,000 and 1,005,965 shares of restricted Comp
• $1,054,000 — ated pursuant to the following formula: $1,054,000/[closing price of Company common stock
• $2.20 — 's common stock at an exercise price of $2.20 per share, issued on October 25, 2022,
• $2.075 — 's common stock at an exercise price of $2.075 per share, issued on June 6, 2023, and
• $3.19 — 's common stock at an exercise price of $3.19 per share issued on June 26, 2023 (the
• $1.62 — stock, at a reduced exercised price of $1.62 per share, in consideration for the Com
• $1.50 — 's common stock at an exercise price of $1.50 per share. The closings of the transact

Filing Documents

• forms-1a.htm (S-1/A) — 2030KB
• ex23-1.htm (EX-23.1) — 4KB
• forms-1_001.jpg (GRAPHIC) — 5KB
• fin_001.jpg (GRAPHIC) — 4KB
• fin_002.jpg (GRAPHIC) — 23KB
• 0001493152-24-012211.txt (&nbsp;) — 8034KB
• mbot-20230930.xsd (EX-101.SCH) — 60KB
• mbot-20230930_cal.xml (EX-101.CAL) — 64KB
• mbot-20230930_def.xml (EX-101.DEF) — 229KB
• mbot-20230930_lab.xml (EX-101.LAB) — 392KB
• mbot-20230930_pre.xml (EX-101.PRE) — 309KB
• forms-1a_htm.xml (XML) — 1402KB

USE OF PROCEEDS

USE OF PROCEEDS 29 MARKET FOR COMMON STOCK 29 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 29

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 30

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 33

BUSINESS

BUSINESS 34 BOARD OF DIRECTORS AND MANAGEMENT 50

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 56 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 62

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 63 SELLING STOCKHOLDERS 64 PLAN OF DISTRIBUTION 65

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 66 LEGAL MATTERS 70 EXPERTS 70 WHERE YOU CAN FIND MORE INFORMATION 70

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS You should rely only on the information that we have provided in this prospectus and any prospectus supplement that we may authorize to be provided to you. We have not, and the selling stockholders have not, authorized anyone to provide you with different information. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus or any prospectus supplement that we may authorize to be provided to you. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information in this prospectus and any prospectus supplement is accurate only as of the date on the cover of the document, regardless of the time of delivery of this prospectus or any prospectus supplement or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. We urge you to carefully read this prospectus and any prospectus supplement, together with the information as described under the heading "Where You Can Find More Information." Unless the context indicates otherwise, as used in this prospectus, the terms "we," "us," "our," the "Company" and "Microbot" refer to Microbot Medical Inc., including our directly and indirectly wholly owned subsidiary. Unless the context otherwise requires, the historical business, financial statements and operations of Microbot include Microbot Medical Ltd., an Israeli corporation ("Microbot Israel") which became a wholly-owned subsidiary of the Company on November 28, 2016. We own or have rights to various U.S. federal trademark registrations and applications, and unregistered trademarks and servicemarks, including LIBERTY . All other trade names, trademarks and service marks appearing in this prospectus are the property of their respective

View Full Filing

View this S-1/A filing on SEC EDGAR